Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2024 - 2025)

Historic Depreciation & Amortization (CF) for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $340000.0.

  • Xilio Therapeutics' Depreciation & Amortization (CF) fell 1052.63% to $340000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2024, which is 1347.37% down from last year.
  • Xilio Therapeutics' Depreciation & Amortization (CF) amounted to $340000.0 in Q3 2025, which was down 1052.63% from $381000.0 recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $497000.0 for Q1 2025, and its period low was $340000.0 during Q3 2025.